The adverse outcome pathway (AOP) for chemically induced liver steatosis involves nuclear receptor binding, microsomal triglyceride transfer protein (MTP) or carnitine palmitoyltransferase I (CPT-1) inhibition, coenzyme A binding and carnitine depletion as the molecular initiating events that lead to triglyceride accumulation (Allen et al. 2014; Vinken 2015). This evidence concerns the gene MTTP and Hepatic steatosis.